European Patent Office Grants Further Patent to Salipro Biotech

In the Lab eNewsletter, Pharmaceutical Technology's In the Lab eNewsletter, March 2022, Volume 17, Issue 3

The European Patent Office has granted another patent to Salipro Biotech, covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.

The European Patent Office has granted another patent to Salipro Biotech, a Swedish biotech company, covering the composition-of-matter, methods, and uses of the company’s novel antigen technology.

According to a Feb. 8, 2022 press release, the “Antigen and method for production thereof” patent (No. EP 3 043 814 B1) will strengthen Salipro Biotech’s proprietary platform technologies to enable the discovery and development of next-generation therapeutics against challenging drug targets.

“We’re constantly increasing our collaborations, partnerships and licensing agreements with major pharma companies on a wide range of challenging drug targets,” said Maria Knudsen, business development director at Salipro Biotech AB, in the press release. “Expanding our already strong patent portfolio further will enable us to increase the value of such collaborations for our partners as well as moving towards building our own discovery pipeline.”

“We’re excited about this important milestone that provides additional protection for our core technologies. The market for therapeutic antibodies, vaccines and biologics is ever expanding,” added Jens Frauenfeld, CEO, Salipro Biotech, in the press release. “Securing these patents protects our innovative platform and further strengthens our position by supplementing our foundational and follow-up patents that have already been granted to Salipro Biotech in many countries, including US, [European Union], China, and Japan.”

Source: Salipro Biotech